Edition:
United Kingdom

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

1,003.80GBp
22 Jun 2018
Change (% chg)

-46.20 (-4.40%)
Prev Close
1,050.00
Open
1,039.20
Day's High
1,057.60
Day's Low
986.00
Volume
608,053
Avg. Vol
211,293
52-wk High
1,064.38
52-wk Low
265.00

Chart for

About

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D... (more)

Overall

Beta: -0.01
Market Cap(Mil.): £282.36
Shares Outstanding(Mil.): 3,106.25
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.00 -- --
ROI: -24.52 2.00 14.38
ROE: -105.55 3.49 16.08

BRIEF-Oxford Biomedica Announces ‍Proposed Placing To Raise About 20.5 Mln STG

* OXFORD BIOMEDICA PLC - ‍PROPOSED PLACING TO RAISE APPROXIMATELY £20.5 MILLION​

09 Mar 2018

Oxford BioMedica wins second $100 million gene therapy contract

LONDON Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

15 Feb 2018

Oxford BioMedica wins second $100 million gene therapy contract

LONDON Britain's Oxford BioMedica has won a second $100 million (£71.2 million) contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

15 Feb 2018

Oxford BioMedica wins second $100 mln gene therapy contract

LONDON, Feb 15 Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

15 Feb 2018

BRIEF-Oxford Biomedica Says ‍Kymriah Receives Priority Review For Adult DLBCL​

* SAYS ‍KYMRIAH RECEIVES PRIORITY REVIEW FOR ADULT DLBCL​ Source text for Eikon: Further company coverage:

17 Jan 2018

Earnings vs. Estimates